Please assess the completion status of the following clinical trial:

Trial Title: Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically confirmed squamous cell carcinoma of the nasopharynx, oropharynx, larynx, hypopharynx, oral cavity~* Patients must be scheduled to receive RT or CRT as definitive treatment or surgery with planned adjuvant RT or CRT treatment post-surgery per surgeon or Head and Neck Cancer (HNC) Tumor Board decision~* Patients should receive their definitive treatment at Wake Forest University (WFU) Cancer Center or at Medical University of South Carolina (MUSC) Cancer Center~* Patients must be active smokers (defined as smoking any cigarette, cigar or pipe in the last 30 days)~* Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document~Exclusion Criteria:~* Patients who receive RT or CRT with palliative intent and have a prognosis of less than one year survival~* Patients who chew tobacco and patients who are not smoking but are exposed to second hand smoking are excluded from this study~* Patients currently using a smoking cessation treatment~* Other known drug use/abuse~* Patients with documented contraindications for bupropion (bupropion hydrochloride), including: bulimia nervosa, anorexia nervosa; use of monoamine oxidase inhibitors in the past two weeks; documented seizure disorders or predisposition to seizure (ie stroke, brain metastases); abrupt withdrawal from alcohol, benzodiazepines, or other sedatives; closed-angle glaucoma~* Patients with diagnosis of major depression or any other psychiatric disorders~* Documented history of allergic reactions attributed to compounds of similar chemical or biologic composition to buproprion~* Any other significant acute or chronic diseases that in the investigator's opinion would exclude the subject from the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (bupropion hydrochloride) (Type: EXPERIMENTAL): Patients receive bupropion hydrochloride PO for 3 days and then BID for up to 1 year post RT/CRT.
- Arm B (varenicline, NRT) (Type: ACTIVE_COMPARATOR): Patients receive smoking cessation treatment tailored to individual smokers based on preference, smoking history and contra-indications. Patients are given the choice of one of the NCCN-recommended first-line pharmacotherapy options for smoking cessation comprised of varenicline PO daily for 1 week and then BID for 12 weeks or combination of nicotine patch and acute NRT for 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Treatment with varenicline or NRT can be extended up to 6 months to 1 year as needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).